19q13-ERCC1 Gene Copy Number Increase in Non–Small-Cell Lung Cancer

2013 ◽  
Vol 14 (5) ◽  
pp. 549-557 ◽  
Author(s):  
Elsa Vanhecke ◽  
Alexander Valent ◽  
Ximing Tang ◽  
Philippe Vielh ◽  
Luc Friboulet ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Copy Number ◽  
Gene Copy Number ◽  
Small Cell ◽  
Gene Copy ◽  
Small Cell Lung ◽  
Number Increase ◽  
Copy Number Increase

scholarly journals Increased MET Gene Copy Number but Not mRNA Level Predicts Postoperative Recurrence in Patients with Non–Small Cell Lung Cancer

2014 ◽  
Vol 7 (5) ◽  
pp. 605-612 ◽  
Author(s):  
Oksana Kowalczuk ◽  
Miroslaw Kozlowski ◽  
Wiesława Niklinska ◽  
Joanna Kisluk ◽  
Barbara Joanna Niklinska ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Copy Number ◽  
Mrna Level ◽  
Gene Copy Number ◽  
Postoperative Recurrence ◽  
Small Cell ◽  
Gene Copy ◽  
Small Cell Lung

Abstract 3098: ERCC1 gene copy number variations in resected non-small cell lung cancer

2012 ◽  
Author(s):  
Luc Friboulet ◽  
Ken A. Olaussen ◽  
Alexander Valent ◽  
Ximing Tang ◽  
Tao Tang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Copy Number ◽  
Gene Copy Number ◽  
Copy Number Variations ◽  
Small Cell ◽  
Gene Copy ◽  
Small Cell Lung

Clinicopathologic Implications of ALK Gene Copy Number Gain in Non-small Cell Lung Cancer

2011 ◽  
Vol 10 (2) ◽  
pp. 87 ◽  
Author(s):  
Seol-Bong Yoo ◽  
Hyojin Kim ◽  
Xianhua Xu ◽  
Ping-Li Sun ◽  
Yan Jin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Copy Number ◽  
Gene Copy Number ◽  
Copy Number Gain ◽  
Small Cell ◽  
Gene Copy ◽  
Small Cell Lung ◽  
Gene Copy Number Gain

Protein expression (PE) and increased IGF1R gene copy number (GCN) in small cell lung cancer (SCLC).

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 10584-10584
Author(s):  
A. Badzio ◽  
M. W. Wynes ◽  
R. Dziadziuszko ◽  
D. Merrick ◽  
M. Pardo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Protein Expression ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Copy Number ◽  
Gene Copy Number ◽  
Small Cell ◽  
Gene Copy ◽  
Small Cell Lung

scholarly journals High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer

2010 ◽  
Vol 5 (3) ◽  
pp. 305-313 ◽  
Author(s):  
Heounjeong Go ◽  
Yoon Kyung Jeon ◽  
Hyo Jin Park ◽  
Sook-Whan Sung ◽  
Jeong-Wook Seo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Copy Number ◽  
Gene Copy Number ◽  
Small Cell ◽  
Gene Copy ◽  
Small Cell Lung

scholarly journals Independent of ErbB1 gene copy number, EGF stimulates migration but is not associated with cell proliferation in non-small cell lung cancer

2013 ◽  
Vol 13 (1) ◽  
pp. 38 ◽  
Author(s):  
Camila Lauand ◽  
Paula Rezende-Teixeira ◽  
Beatriz Araújo Cortez ◽  
Evandro Luís de Oliveira Niero ◽  
Gláucia Maria Machado-Santelli
Keyword(s):  
Lung Cancer ◽  
Cell Proliferation ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Copy Number ◽  
Gene Copy Number ◽  
Small Cell ◽  
Gene Copy ◽  
Small Cell Lung

Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer

Lung Cancer ◽  
2006 ◽  
Vol 53 (1) ◽  
pp. 117-121 ◽  
Author(s):  
Masaki Tokumo ◽  
Shinichi Toyooka ◽  
Shuji Ichihara ◽  
Kadoaki Ohashi ◽  
Kazunori Tsukuda ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Copy Number ◽  
Gene Copy Number ◽  
Small Cell ◽  
Gene Copy ◽  
Small Cell Lung ◽  
Double Mutation

Exploratory analysis of EGFR FISH criteria in Japanese non-small cell lung cancer patients treated with gefitinib

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 7599-7599
Author(s):  
K. Kazuo ◽  
L. E. Morrison ◽  
H. Kimura ◽  
T. Sone ◽  
T. Araya ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Copy Number ◽  
Gene Copy Number ◽  
Small Cell ◽  
Gene Copy ◽  
Control Fish ◽  
Small Cell Lung ◽  
Egfr Gene

7599 Background: In the phase III Iressa (gefitinib) Survival Evaluation in Lung cancer (ISEL) trial, high epidermal growth factor receptor (EGFR) gene copy number was a predictor of a gefitinib effect on survival in patients (pts) with refractory advanced non-small-cell lung cancer (NSCLC) (hazard ratio 0.61 vs 1.16 for high vs low copy number; p=0.045) [JCO 2006;24:5034–42]. Although EGFR mutation status may predict response to gefitinib in Japanese pts, there is insufficient data to clarify if high EGFR gene copy number assessed by fluorescence in situ hybridization (FISH) is predictive in these pts. This analysis investigated the applicability of both published Colorado FISH criteria (Colorado Univ) and new FISH criteria to Japanese NSCLC pts. Methods: 58 tumor specimens from gefitinib-treated Japanese pts were analyzed using Vysis LSI EGFR and CEP7 (chromosome 7 control) FISH probes. Specimens were classed as FISH+ or - using Colorado and exploratory (EGFR/cell; CEP7/cell; EGFR/CEP7; % of cells with various numbers of EGFR or CEP7 signals) criteria. Results: Of the 58 pts, 17 (29%) had an objective response (OR). Using Colorado criteria, OR was 50% in the 14 FISH+ pts vs 23% in the 44 FISH- pts (2-sided Fisher's exact test p=0.089). There was a trend for an association between FISH+ status and improved survival (log rank p=0.15). Defining FISH+ as specimens with =5% cells containing >5 EGFR signals, OR was significantly better among FISH+ pts vs FISH- pts (p=0.0030; 52% of the 23 FISH+ pts responding vs 14% of the 35 FISH- pts). A survival advantage was not indicated. Defining FISH+ as =74% of cells with EGFR or CEP7 loss (<2 signals) or gain (>2 signals), OR was significantly better among FISH+ pts vs FISH- pts (p=0.043; 45% of the 22 FISH+ pts responding vs 19% of the 36 FISH- pts). Association with survival had marginal significance (log rank p=0.061). Conclusions: These preliminary data have identified loss or gain of EGFR and CEP7 abnormality as promising biomarkers for response to gefitinib in Japanese NSCLC patients. Analysis of these markers for correlation with time to progression is ongoing. Investigation of these potential markers in other cohorts of patients is worthy of further evaluation. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document